Antibacterial activity of gentamicin-bonded gelatin-sealed polyethylene terephthalate vascular prostheses.
OBJECTIVE
To create an antibiotic-modified vascular prosthesis with a prolonged bactericidal activity, susceptible to endothelialisation.


METHODS
We used a covalent method of gentamicin sulphate immobilisation to polyethylene terephthalate prosthesis sealed with gelatin. Antibacterial activity was assayed in Luria-Bertani medium against Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa strains. Prosthesis endothelialisation was performed using bovine aorta endothelial cells (BAEC).


RESULTS
Gentamicin was bound to vascular prostheses in the amount of 12g per kg of prosthesis. Ninety-seven percent of antibiotic bound in covalent way and remained on the biomaterial for at least 30 days during shaking in PBS solution. Gentamicin-modified prostheses exerted bactericidal or bacteriostatic effect on growth of clinical and reference bacterial strains, prevented biofilm formation and were highly susceptible to endothelialisation. BAEC viability exceeded 90%, which indicated that gentamicin-vascular prostheses were not toxic for these cells.


CONCLUSIONS
Covalent gentamicin immobilisation resulted in effective antibacterial protection of vascular prostheses against clinical and reference strains of S. aureus, E. coli and P. aeruginosa and allowed for a strong adherence of endothelial cells to antibiotic-modified prostheses.
Ginalska
G
G
Department of Biochemistry, M. Curie-Sklodowska University, 3 Maria Curie-Sklodowska Square, 20-031 Lublin, Poland. ginal@hermes.umcs.lublin.pl
Osinska
M
M
Uryniak
A
A
Urbanik-Sypniewska
T
T
Belcarz
A
A
Rzeski
W
W
Wolski
A
A
D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001807:Blood Vessel Prosthesis; D004926:Escherichia coli / Q000187:drug effects; D005780:Gelatin; D005839:Gentamicins / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D008826:Microbial Sensitivity Tests; D018613:Microscopy, Confocal; D011093:Polyethylene Terephthalates; D011474:Prosthesis Design; D016459:Prosthesis-Related Infections / Q000517:prevention & control*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013211:Staphylococcus aureus / Q000187:drug effects
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D011093:Polyethylene Terephthalates; D005780:Gelatin